Tag: CE

New York, NY – August 28, 2025 – As part of its marketplace monitoring program, BBB National Programs’ National Advertising Division recommended that Next Health discontinue or modify certain health-related claims made for its Executive Physical. Because Next Health did not provide a statement of intent to comply with those recommendations, the National Advertising Division (NAD) is referring this matter to the Federal Trade Commission (FTC).

Next Health is a wellness and longevity clinic offering personalized medical services, including an Executive Physical membership.

At issue for NAD were express and implied claims regarding Next Health’s Executive Physicals, including statements that consumers can “live the longest, most fulfilling life,” and that NextHealth’s services ensure clients can live longer, disease-free lives.

NAD examined the wording and context of Next Health’s claims, specifically, a video on its website featuring Founder and CEO, Dr. Shah, stating the Executive Physical will help consumers “live the longest, most fulfilling life” without any qualifications.

NAD determined that the challenged advertising reasonably conveyed the message that NextHealth’s services ensure that clients can live longer, healthier lives. This message is reinforced by the medical graphics and text on the website describing Next Health as “a health optimization and longevity center” and the Executive Physical as a product that promotes “a healthier and longer future.” Moreover, these claims and images of medical staff, equipment, and client testimonials appear with no disclosures or other qualifiers.  

NAD found that although Next Health’s evidence provided valuable insights into individual modalities, it did not constitute reliable scientific evidence that Executive Physical’s combination of testing and purported diagnostic capabilities provides the claimed health benefits, which include the early detection of serious diseases.

Therefore, NAD determined that the evidence did not provide a reasonable basis for the challenged health claims and recommended that they be discontinued.

During the inquiry, Next Health permanently discontinued certain express claims. NAD did not review the discontinued claims on their merits and will treat the claims, for compliance purposes, as though NAD recommended they be discontinued.

Next Health declined the opportunity to provide an advertiser’s statement, indicating instead that it had “implemented the permanent discontinuation of the specific express claims identified in the decision, but that it stands by the accuracy and substantiation of the remaining claims.”

Accordingly, pursuant to NAD/NARB Procedures, because the advertiser has failed to submit an Advertiser’s Statement as required, NAD is referring this matter to the appropriate governmental agency, the FTC.

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than a dozen globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create a fairer playing field for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division of BBB National Programs provides  independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. The National Advertising Division reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.

Dun & Bradstreet’s proprietary corporate data complements LexisNexis’ repository of legal data and licensed news content – including the industry’s largest collection of GenAI-approved news datasets

New York, NY – Aug. 28, 2025 – The Nexis Solutions division of LexisNexis^® Legal & Professional, a leading global provider of AI-powered analytics and decision tools, today announced an expansion of its collaborative Generative AI (GenAI) data licensing agreement with Dun & Bradstreet, a leading global provider of business data and analytics. The license allows for Dun & Bradstreet’s portfolio of corporate records, including corporate structures, executive information, financial metrics and more, to be easily searchable and summarized with Nexis Solutions products.

Dun & Bradstreet’s inclusion enhances the Nexis Solutions data ecosystem.  With industry-leading, AI-ready insights on over 600 million global entities, the Dun & Bradstreet content brings unmatched depth and breadth to the combined repository of legal business intelligence and licensed news content Nexis Solutions is known for. That repository includes the industry’s largest collection of GenAI-approved news datasets from outlets such as The Associated Press, McClatchy, Gannett and thousands more. This enriched data foundation, combined with the speed and scalability of GenAI, empowers business and legal professionals to conduct more precise research, accelerate risk assessments, and make confident, data-driven decisions with greater efficiency. This dataset is available across the Nexis Solutions portfolio including SaaS products such as the award-winning GenAI-powered Nexis+ AI^® and APIs such as Nexis^® Data+.

“Our decades-long relationship with Dun & Bradstreet, which now incorporates GenAI approval, continues our best practice of collaborating with industry-leading publishers and data providers to ensure our customers have access to the most accurate corporate data and news they need to make business-critical decisions every day,” said Todd Larsen, President, Nexis Solutions. “This content, combined with our leading GenAI technology, enables organizations to fuel decision making for a competitive market advantage.”

“Combining trusted, authoritative data from Dun & Bradstreet and LexisNexis into one platform will empower enterprises across industries to make better informed decisions at the speed of AI,” said Dani McCormick, Vice President of Product, Nexis Solutions. “Accelerating data-intensive corporate research tasks like market sizing, opportunity identification, competitive intelligence, and executive profiling, delivers significant productivity and cost-efficiency gains while also allowing enterprises to be more agile and focus resources on the most impactful, value-creating initiatives.”

Dun & Bradstreet’s Data Cloud is one of the world’s most comprehensive and trusted sources of business intelligence. Dun & Bradstreet’s data will enable Nexis Solutions customers, including corporations, financial institutions, consultancies, academic institutions, nonprofits, and other organizations, to streamline corporate research, analysis and due diligence across key topics, trends, and entities, and power a variety of GenAI initiatives. LexisNexis has leveraged Dun & Bradstreet data across a broad range of Nexis Solutions offerings, including Nexis^® and Nexis Newsdesk^®, since 1996.

“Our alliance with LexisNexis represents a leap forward in expanding access to Dun & Bradstreet’s unparalleled global data,” said Anna Krayn, General Manager, Partnerships & Alliances at Dun & Bradstreet. “This collaboration, integrating Dun & Bradstreet’s trusted, high-quality data, spanning financials, ownership structures, officers and directors, and more, into LexisNexis’ GenAI platforms, empowers legal and business professionals with faster, more accurate research and decision-making. It enhances operational transparency and delivers measurable strategic value in today’s increasingly complex and data-driven environment.”

For more information about LexisNexis please visit www.lexisnexis.com.

For more information about Dun & Bradstreet data and analytics, please visit www.dnb.com.

About LexisNexis Legal & Professional

LexisNexis^® Legal & Professional provides legal, regulatory, and business information and analytics that help customers increase their productivity, improve decision-making, achieve better outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis^® and Nexis^® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 11,800 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

About Dun & Bradstreet

Dun & Bradstreet, a leading global provider of business decisioning data and analytics, enables companies around the world to improve their business performance. Dun & Bradstreet’s Data Cloud fuels solutions and delivers insights that empower customers to accelerate revenue, lower cost, mitigate risk, and transform their businesses. Since 1841, companies of every size have relied on Dun & Bradstreet to help them manage risk and reveal opportunity. For more information on Dun & Bradstreet, please visit www.dnb.com.

Media Contact
Leela Bozonelis, Global Product Marketing Director    
Nexis Solutions, a Division of LexisNexis                      

leela.bozonelis@lexisnexis.com; 929-383-8781

Dun & Bradstreet Media Contact

pr@dnb.com

New York, NY – August 27, 2025 – Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs’ National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division’s (NAD) inquiry.

Vertex and Maze are competitors developing clinical-stage treatments for APOL1-Mediated Kidney Disease (AMKD).

At issue for NAD were express and implied claims made by Maze in investor presentations, press releases, and public filings. Vertex requested that NAD review Maze’s claims regarding the efficacy of MZE829, small-molecule compound treatment of AMKD being developed by Maze, as compared to inaxaplin, Vertex’s drug candidate for AMKD.

Maze declined to participate in the NAD process, stating that it does not currently sell any product and does not advertise MZE829. Given Maze’s decision not to participate in the self-regulatory process, NAD will refer the matter to the appropriate government agencies.

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Pursuant to NAD/NARB Procedures, this release may not be used for promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division (NAD) of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and creating fair competition for business.

New LexisNexis Intellectual Property Solutions report delivers data-driven insights to inform the debate on fair SEP licensing versus over-enforcement.

NEW YORK, August 27, 2025— LexisNexis^® Legal & Professional, a leading global provider of AI-powered analytics and decision tools, today announced the release of its U.S. SEP Litigation Report 2025, showing that litigation cases involving standard-essential patents (SEPs) has risen from 118 in 2014 to 223 in 2024. With more than 200 cases a year now being filed, a growing share is driven by Patent Assertion Entities (PAEs), which account for more than 40% of recent disputes—nearly double their share from a decade ago.

This surge is fueled by rapid adoption of 4G/5G, Wi-Fi, video and audio codecs, and Qi wireless charging, alongside policy uncertainty. While no definitive federal guidance on SEP enforcement has emerged, evolving case law around injunctions, FRAND royalties, and venue dynamics continues to shape litigation strategies.

“SEP litigation in the U.S. has entered a phase of sustained volume and complexity,” said Tim Pohlmann, Managing Director Americas and Director SEP Analytics for LexisNexis^® Intellectual Property Solutions. “With PAEs driving filings and AI reshaping portfolio analysis, IP professionals must transition from reactive defense to proactive, data-driven portfolio management.”

Annual U.S. SEP litigation cases by filing year and plaintiff type’s share
(PAE, NPE, Operating Company), 2014 – 2024)

The U.S. SEP Litigation Report 2025 leverages AI-powered analytics quantifying portfolio shares, and benchmarking FRAND rates to help bring clarity to U.S. patent litigation patterns.

Key Findings from the Report

• PAEs Share in SEP Disputes Increases: Almost half of all U.S. SEP litigation involves PAEs, many focused on narrow technology areas such as Wi-Fi or cellular SEPs.
• Venue Concentration: The Eastern District of Texas remains the most active forum, followed by Delaware and the Western District of Texas. The ITC is also seeing more SEP investigations, offering plaintiffs potent exclusion remedies.
• Standards in Dispute: The most litigated standards include cellular, Wi-Fi, video and audio codecs, and Qi wireless charging—impacting industries from smartphones and streaming to automotive and medical devices.
• Key Parties and Law Firms: On the plaintiff side, Devlin Law Firm and Farnan are the most active representatives, while Fish & Richardson and Gillam & Smith are among the leading defense firms. Defendants include major handset makers (Samsung, Apple, Google), computer OEMs (Dell, Lenovo, HP), and carriers (Verizon, T-Mobile, AT&T).

For licensors, the report highlights how to benchmark portfolios, track competitor enforcement, and leverage data-driven analytics to strengthen FRAND positions. For licensees, it offers visibility into litigation waves, plaintiff activity, and venue trends to better anticipate risks and prepare defense strategies. By presenting both perspectives, the U.S. SEP Litigation Report 2025 helps reduce information asymmetry in FRAND negotiations, enabling more transparent, predictable, and efficient outcomes for all parties.

The LexisNexis^® U.S. SEP Litigation Report 2025 draws on data from LexisNexis^® IPlytics and the Global Patent Litigation Database, analyzing U.S. cases from 2014–2024 across cellular, Wi-Fi, video, and audio codecs, IETF, JEDEC, and Qi wireless charging standards.

The report provides a breakdown of SEP litigation by filing date and plaintiff type (PAE, NPE, operating company) and includes detailed rankings of the top 50 SEP plaintiffs and defendants by total case count and by standard. It also profiles the top 50 law firms representing plaintiffs and defendants, ranked by overall caseload and standard-specific activity, and highlights the top 10 courts by average annual SEP case volume and growth rates. Methodological notes on AI-enhanced essentiality estimates are included, along with strategic guidance for SEP stakeholders on applying data-driven portfolio management, objective FRAND benchmarks, venue-specific tactics, transparency initiatives like Cellular Verified, and ongoing refinement of essentiality assessments.

For more details and to access the full premium report, visit: www.lexisnexisip.com/us-sep-litigation-trends

About LexisNexis Legal & Professional

LexisNexis^® Legal & Professional provides legal, regulatory, and business information and analytics that help customers increase their productivity, improve decision-making, achieve better outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis^® and Nexis^® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 11,800 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

LexisNexis^® Intellectual Property Solutions brings clarity to innovation for businesses worldwide. We enable innovators to accomplish more by helping them make informed decisions, be more productive, comply with regulations, and ultimately achieve a competitive advantage for their business. Our broad suite of workflow and analytics solutions (LexisNexis^® PatentSight+, LexisNexis^® Classification, LexisNexis^® TechDiscovery, LexisNexis^® IPlytics, LexisNexis PatentOptimizer^®, LexisNexis PatentAdvisor^®, and LexisNexis TotalPatent One^®, LexisNexis^® IP DataDirect), enables companies to be more efficient and effective at bringing meaningful innovations to our world. We are proud to directly support and serve these innovators in their endeavors to better humankind.  

The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

The market capitalization is approximately £72.6bn,  €83.2bn,  $97.5bn.

*Note: Current market capitalization can be found at http://www.relx.com/investors

Media Contact

Andrew Weinstein 
Andrew.Weinstein@LexisNexis.com

LexisNexis  |  Intellectual Property Solutions  
Bringing clarity to innovation

New York, NY – August 25, 2025 – Following a challenge brought by competitor GuruNanda, LLC, BBB National Programs’ National Advertising Division determined that The Procter & Gamble Company (P&G) provided a reasonable basis for whitening claims for its Crest 3D Whitestrips products.

At issue for the National Advertising Division (NAD) were P&G’s express claims “[X] Levels Whiter” and “Levels [X] Whiter” that appear on the product labeling of Crest 3D Whitestrips, with the levels ranging from “4” to “34” depending on the product, as well as implied claims that whiteness improvement is a typical result achieved by the majority of consumers who use the products.

NAD found that P&G’s clinical studies and meta-analysis provided a reasonable basis for the claims, supporting P&G’s express “levels whiter” claims. NAD did not find that the “[X] Levels Whiter” claims convey the message that the products will whiten teeth the number of shades specified in the claims.

Additionally, NAD determined that P&G provided a reasonable basis for the implied claim that the advertised whiteness improvement is a typical result achievable by the majority of consumers.

In its advertiser’s statement, P&G stated it “appreciates the NAD’s thorough consideration of the advertising.”

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than a dozen globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create a fairer playing field for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. The National Advertising Division reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.

New York, NY – August 20, 2025 – In a challenge brought by competitor Nurture, LLC, BBB National Programs’ National Advertising Division determined Kendal Nutricare Limited provided a reasonable basis for certain claims made for its Kendamil infant formulas, but recommended Kendal modify or discontinue other claims, which the National Advertising Division (NAD) determined were not supported by the record.

“Natural” and “Clean” Claims

Nurture argued that the words and images on Kendal’s website and product packaging convey the unsupported message that Kendamil products are “all natural.” NAD found that in the context in which the words and images appeared, Kendal did not make an unqualified “all natural” claim about its infant formula.  

NAD determined Kendal established a reasonable basis for the challenged “natural” claims, including “Wholesome by Nature” and “Natural Goodness. Creamy whole milk & lactose from grass-fed cows,” because they are tied to specific natural and minimally processed ingredients.

“Clean” Claims

Nurture also challenged two “clean” claims that appear on the Kendamil website. As Kendamil did not provide support for the “clean” claims, NAD recommended the challenged clean claims either be discontinued or modified.

Additives Claims

NAD determined the claim “We don’t do palm oil, corn syrups, soy, fish oil or other cheap additives,” in context, makes a comparison to ingredients in other products, characterizing them as “cheap” and problematic. However, there was no evidence demonstrating these ingredients are cheap or problematic additives when present in infant formula.

NAD therefore recommended Kendal discontinue or modify the additive claims.

More Nutritious Claims

In support of claims that its organic formulas are more nutritious than those of its competitors, Kendamil relied on several research studies that NAD found, while informative, were not a good fit for the challenged more nutritious claims because they did not evaluate Kendamil’s products or any competitor products.

As a result, NAD recommended Kendal discontinue or modify the challenged comparative superiority claims.

Whole Milk and MFGM Claims

NAD found that one message reasonably conveyed by the challenged MFGM claims is that Kendamil products contain natural MFGM because they are made with whole milk fats that are similar to breastmilk, which also contains beneficial naturally occurring MFGM.

NAD found that Kendal’s 2021 Nutrients study was not a good fit for the challenged MFGM claims because the study did not examine the Kendamil formula. The study showed, however, that milk fat contains MFGM and that MFGM supports cognitive development in infants. Accordingly, NAD found that because Kendamil formulas include whole milk fats, Kendal had established a reasonable basis for the challenged MFGM claims.

Anti-Inflammatory Claims

NAD found one message reasonably conveyed by a challenged social media post is that Kendamil Goat infant formula contains prebiotic GOS in sufficient amounts to provide anti-inflammatory benefits.

NAD concluded, however, that Kendal did not provide competent and reliable scientific evidence to support the claim. NAD therefore recommended that Kendal discontinue or modify its advertising to avoid conveying that Kendamil’s Goat Infant Formula has prebiotic GOS that is “anti-inflammatory” or that it helps to protect against inflammation.

Consumer Reviews

NAD determined that there was no evidence that the reviews on the Kendamil product website are false or fake, as prohibited by the FTC’s Rule, or that the reviews misrepresent the individual reviewer’s experience. Additionally, NAD determined there was no evidence of a material connection between Kendal and the author of the challenged consumer review requiring disclosure.

“FDA Approved” Claim

NAD recommended Kendal discontinue the “FDA Approved” claim on product packaging to avoid conveying the misleading message that Kendamil’s formula is endorsed or formally approved by the FDA.

In its advertiser statement, Kendal stated that it “agrees to comply with NAD’s recommendations” and “thanks NAD for its thorough review.”

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for advertising or promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, promote fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. The National Advertising Division reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and promoting fair competition for business.

New York, NY – August 19, 2025 – In an inquiry brought by competitor GuruNanda, LLC, BBB National Programs’ National Advertising Division determined that The Procter & Gamble Company (P&G) provided a reasonable basis for the name and product performance claims for its Crest 3D White Brilliance Deep Stain Remover Toothpaste. However, the National Advertising Division (NAD) recommended P&G discontinue or modify its “extra strength fluoride” claim.

NAD reviewed express claims such as that the toothpaste removes “deep stains,” dissolves stain bonds, and has superior whitening technology, as well as the implied claims that it removes intrinsic stains, prevents new stains, and provides superior enamel protection than standard concentrations. 

The challenged claims appear on the product label and are featured throughout P&G’s advertising, including on the Crest website and product pages for third-party retailers.

Product Name and Performance Claims

P&G provided scientific evidence and clinical studies to support the product’s whitening, stain removal, and stain prevention claims and cited several studies on stain repellency technology.

NAD determined P&G’s evidence established a reasonable basis for the challenged express product performance claims, including the product name, and found certain challenged implied claims were not conveyed.

“Extra Strength Fluoride” Claim

NAD reviewed the claim “REPAIR – Extra strength fluoride remineralizes enamel to strengthen teeth” as it appears on product packaging and P&G’s website and determined the claim goes beyond what is permitted by the FDA monograph, which makes no reference to using the term “extra-strength” to describe remineralization and strengthening benefits.

Therefore, NAD recommended the claim be discontinued or modified to avoid conveying the unsupported message that the product’s higher fluoride content provides greater enamel strengthening and protection than standard concentrations.

In its advertiser statement, P&G stated it “will comply with NAD’s decision.”

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than a dozen globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create a fairer playing field for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. The National Advertising Division reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.

New York, NY – August 18, 2025 — As part of its routine marketplace monitoring, BBB National Programs’ National Advertising Division challenged certain express claims and testimonials promoted by The Good Feet Store for its Arch Support System and recommended discontinuing certain unsupported pain relief claims.

Good Feet sells arch supports, including its Arch Support System. At issue for the National Advertising Division (NAD) was the substantiation of certain express claims asserting the product is clinically proven to provide significant pain relief and is engineered to “help you live the life you love without pain,” as well as customer testimonials describing how Good Feet’s arch supports instantly or completely eliminated pain and foot problems.

NAD reviewed the clinical studies provided by Good Feet and found that, due to limitations in certain study parameters, the studies were insufficiently reliable to support the challenged express pain relief claims and testimonials. As a result, NAD recommended that Good Feet discontinue them.

In its advertiser statement, Good Feet said it “will comply with NAD’s recommendations.”

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for advertising or promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, promote fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. The National Advertising Division reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy.

New York, NY – August 14, 2025 — BBB National Programs’ National Advertising Division determined Caraway Home, Inc. supported its “free of PFAS” and “non-toxic” claims for its cookware, but recommended Caraway discontinue or modify certain comparative claims suggesting that traditional nonstick cookware is harmful to consumer health due to the presence of “forever chemicals” and that Caraway’s cookware is a safer, non-toxic alternative.

The Cookware Sustainability Alliance (CSA), a coalition of cookware manufacturers, challenged claims made by Caraway, a ceramic nonstick cookware maker. CSA members produce a range of cookware, including those coated with polytetrafluroethylene (PTFE) as well as ceramic coated cookware.

The National Advertising Division (NAD) reviewed the express and implied messages in Caraway’s claims, which appeared across its social media, website, video, and email marketing materials.

The PFAS and Harmful Chemicals Claims

NAD found that Caraway’s advertising conveys the messages that competitor nonstick cookware contains and exposes consumers to harmful chemicals, can release toxins into your food and home, can make you sick, and that competitor nonstick cookware is harmful to gut health and kidney function.

NAD reviewed evidence submitted by Caraway, including third-party lab testing and various studies, but found that most of the studies offered were not a good fit for the challenged claims. In addition, NAD noted that the broad challenged claim, “Most traditional cookware is made with forever chemicals and when they are overheated, they can release those same toxins into your food and home” is not supported by the record.

NAD therefore concluded that Caraway did not meet its burden of providing a reasonable basis for claims that competing nonstick cookware is toxic. Accordingly, NAD recommended that Caraway discontinue the challenged express claims and modify its advertising to avoid conveying that misleading message. Alternatively, Caraway may modify its claims to clearly and conspicuously disclose the circumstances under which consumers would be exposed to PTFE fumes during ordinary use of traditional nonstick cookware.

Non-Toxic Ceramic Claims

Caraway’s advertising makes a number of comparative safety claims, contrasting its competitor’s products as created with harmful chemicals while its own cookware is safe and naturally nonstick (as opposed to unnaturally nonstick).

NAD concluded that Caraway has a reasonable basis to claim its cookware is free of PFAS and non-toxic but did not provide sufficient evidence to support comparative claims that competitor cookware is unsafe or less safe.

Therefore, NAD recommended Caraway avoid making such safety claims in a comparative context or a context that conveys the message that competitor nonstick cookware is toxic, and discontinue the expressly comparative challenged claims:

• “Non-Toxic Swaps. Ditch the toxins and cook cleaner with Caraway!”
• “PFAS are ‘forever chemicals’ commonly used in non-stick cookware … but never used in Caraway products.”

 Teflon Flu Claims

Caraway’s social media post claims Teflon flu cases are rising and presents its cookware as a healthier alternative. Although Caraway submitted articles citing a rise in Teflon flu cases, it provided no source data or historical trends to support an increase so NAD recommended Caraway discontinue the claim.

Because NAD found Caraway’s claims about the toxicity of competitor nonstick pans to be unsubstantiated, NAD recommended Caraway avoid making Teflon flu claims in a context that would suggest that competitive cookware is toxic or likely to cause Teflon flu.

In its advertiser statement, Caraway stated that although it “respectfully disagrees with the NAD’s finding,” it “values the opportunity to participate in the NAD’s review process and will comply with the NAD’s decision.”

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for advertising or promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, promote fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. The National Advertising Division reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy,

ANN ARBOR, MI — When guests left Keith and Sarah’s wedding, they didn’t leave with a champagne flute or a bag of candy—they left with a piece of art. The couple’s favorite mountain was immortalized in a Motawi tile, its rich blue glaze capturing the place they loved most, with their names and wedding date fired right into the back.

This is the promise of Motawi Tileworks’ new Custom Commemorative Tile Collection—transforming logos, artwork, and milestone moments into handcrafted commemorative gifts that last for generations.

Handmade from start to finish in Ann Arbor, Michigan, these custom ceramic tiles combine artistry, personalization, and craft tradition. They’re perfect for artists, organizations, and event hosts who want to celebrate an occasion with meaning and beauty.

“When we create a commemorative tile, we’re not just making an object—we’re capturing a moment in time and giving it permanence. Long after the event is over, the story still lives in the tile,” says Nawal Motawi, founder and artistic director.

Motawi Commemorative Tiles are ideal for:

• Business & nonprofit events and anniversaries

• Donor recognition & capital campaigns

• Bar and Bat Mitzvahs, quinceañeras, weddings & graduations

• Limited-edition merchandise for institutions, museums & gift shops

• Artist collaborations, exhibitions & VIP gifting

• Hospitality & restaurant openings

• Awards, retirements & executive thank-you gifts

Two distinctive tile styles are available:

• Polychrome Art Tile – Hand-glazed in vibrant color, rich with detail

• Relief Tile – Sculptural and monochrome, with elegant dimension

Clients begin by submitting a logo, illustration, or design. Motawi’s design team adapts it for tile production, sculpts a custom mold, and hand-glazes each tile before firing it in the kiln. The setup fee includes converting the artwork into a tile-ready file and, if desired, embossing the back with names, dates, and locations.

Pricing starts at a few thousand dollars for 3×3 tiles (includes mold setup + 100 finished tiles) and can exceed $10,000 for larger, intricate polychrome designs.

“Having my woodblock prints rendered into Motawi tile felt like my work had been immortalized,” said artist Yoshiko Yamamoto, a longtime collaborator.

Sample Images:

1. Mountain Lakes: Tile in Arts & Crafts style

2. Villarica: Wedding favor, front and back, personalized with names and date

3. University of Michigan Commemorative Tile: Donor recognition

4. U.S. Open 2008: Event merchandise for a major sporting event

5. The Gamble House: Museum gift shop tile in relief style

6. Unitarian Church: Custom commemorative gift for congregation

Quick Facts

• Tile Sizes: 3×3 to 4×8 and larger custom formats

• Styles: Polychrome Art Tile, Relief Tile

• Pricing: Starting at a few thousand dollars for 3×3 (includes 100 tiles & custom mold)

• Lead Time: Up to 6 months from design approval

• Personalization: Logos, text, dates, locations can be added to the back of each tile

• Production: Handcrafted in Ann Arbor, Michigan, using Motawi’s signature Cuenca hand-glazing technique

Learn more or start a project: motawi.com/pages/commemorative-tile

Inquiries for commemorative tiles: commemoratives@motawi.com
Press inquiries: Greg Anderson | grega@motawi.com